Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | CASP3 | P42574 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16193637 | 0.89 | ALOX15 (0.61) | MEN1KMT2ANPC1RAB9ACASP3 | |
| SCHEMBL1131165 | 0.89 | CASP3 (0.61) | MEN1KMT2ANPC1RAB9ACASP3 | |
| SCHEMBL8479003 | 0.87 | CASP3 (0.62) | MEN1KMT2ANPC1RAB9ACASP3 | |
| SCHEMBL29952405 | 0.85 | CASP3 (0.54) | MEN1KMT2ANPC1RAB9ACASP3 | |
| SCHEMBL1095126 | 0.85 | CASP3 (0.58) | MEN1KMT2ANPC1RAB9ACASP3 | |
| SCHEMBL29956641 | 0.85 | CASP3 (0.53) | MEN1KMT2ANPC1RAB9ACASP3 | |
| SCHEMBL12772987 | 0.82 | NPC1 (0.58) | NPC1RAB9ACASP3MGLLMAOB | |
| SCHEMBL4355908 | 0.82 | NPC1 (0.55) | MEN1KMT2ANPC1RAB9ACASP3 | |
| SCHEMBL14793789 | 0.81 | NPC1 (0.57) | MEN1KMT2ANPC1RAB9ACASP3 | |
| SCHEMBL3795024 | 0.80 | POLB (0.68) | MEN1KMT2ANPC1RAB9AMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | MEN1 174/4885KMT2A 1474/4885NPC1 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.